Final results of Lemminkäinen's rights offering: the

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Final results of Lemminkäinen's rights offering: the Offering was oversubscribed

LEMMINKÄINEN CORPORATION  STOCK EXCHANGE RELEASE 23 SEPTEMBER 2014  AT 10:30 A.M.

Not for publication or distribution, directly or indirectly, in or into Australia, Canada, Hong Kong special administrative region of the People's Republic of China, Japan, New Zealand, South Africa, Singapore or the United States or any other jurisdiction in which the distribution or release would be unlawful.

FINAL RESULTS OF LEMMINKÄINEN’S RIGHTS OFFERING: THE OFFERING WAS OVERSUBSCRIBED

  • Rights offering oversubscribed by 27.5 per cent
  • Gross proceeds of approximately EUR 29.3 million
  • Total number of shares in Lemminkäinen to increase to 23 219 900 shares
  • Due to oversubscription, the underwriting was not utilised

The Board of Directors of Lemminkäinen Corporation (“Lemminkäinen” or the “Company”) has today approved all subscriptions made pursuant to subscription rights in the rights offering that ended on 17 September 2014 (the “Offering).

A total of 4 549 626 shares were subscribed for, representing approximately 127.5 per cent of the 3 569 724 shares offered in the Offering (the “Offer Shares”). 3 531 776 shares were subscribed for pursuant to subscription rights, representing approximately 98.9 per cent of all Offer Shares, and 1 017 850 shares were subscribed for without subscription rights in the secondary subscription, representing approximately 28.5 per cent of all Offer Shares. Of the Offer Shares subscribed for without subscription rights, 37 948 Offer Shares were allocated to subscribers in proportion to the number of subscription rights exercised by these subscribers. The underwriting provided by Danske Bank A/S, Helsinki Branch (“Danske Bank”) was not utilised.

The subscription price was EUR 8.20 per Offer Share, and Lemminkäinen raised gross proceeds of approximately EUR 29.3 million through the Offering. As a result of the Offering, the total number of shares in Lemminkäinen will increase to 23 219 900 shares. The Offer Shares will carry all ordinary shareholder rights in Lemminkäinen, including the right to receive dividends and other distributions of funds, if any, as of the registration of the Offer Shares with the Finnish Trade Register, on or about 25 September 2014.

Trading in interim shares (LEM1SN0114), representing the Offer Shares subscribed for pursuant to subscription rights, commenced on 18 September 2014. The interim shares will be combined with Lemminkäinen’s ordinary shares (LEM1S) on or about 24 September 2014. Trading of the Offer Shares will commence on the official list of NASDAQ OMX Helsinki Ltd from on or about 25 September 2014. The allocated Offer Shares subscribed for without subscription rights will be recorded on the subscriber’s book-entry account directly as ordinary shares on or about 25 September 2014.

Lemminkäinen will confirm the allocations of subscriptions for Offer Shares subscribed for without subscription rights (secondary subscription) by mail. The subscription price paid for the unallocated Offer Shares will be refunded to such subscribers on or about 26 September 2014 in accordance with the terms and conditions of the Offering.

Danske Bank acted as the Lead Manager of the Offering.

LEMMINKÄINEN CORPORATION
Corporate Communications


ADDITIONAL INFORMATION:

Ilkka Salonen, CFO
Tel. +358 2071 53304
Ilkka.salonen@lemminkainen.com


Katri Sundström, Head of Investor Relations
Tel. +358 2071 54813
katri.sundstrom@lemminkainen.com

DISTRIBUTION:
NASDAQ OMX Helsinki
Key media

ww.lemminkainen.com


Together with our customers we create conditions that make living, working and travelling functional, safe and healthy. We operate in northern Europe and employ about 6,000 professionals. In 2013, our net sales were about EUR 2.0 billion. Lemminkäinen Corporation's share is quoted on NASDAQ OMX Nordic Exchange Helsinki. www.lemminkainen.com

DISCLAIMER

The information contained herein is not for publication or distribution, directly or indirectly, in or into Australia, Canada, the Hong Kong special administrative region of the People's Republic of China, Japan, New Zealand, South Africa, Singapore or the United States. The issue, exercise or sale of securities in the offering are subject to specific legal or regulatory restrictions in certain jurisdictions. The Company assumes no responsibility in the event there is a violation by any person of such restrictions.

The information contained herein shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction. Investors must neither accept any offer for, nor acquire, any securities to which this document refers, unless they do so on the basis of the information contained in the applicable prospectus published by the Company.

These written materials do not constitute an offer for sale of securities in the United States, nor may the securities be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended, and the rules and regulations thereunder. There is no intention to register any portion of the offering in the United States or to conduct a public offering of securities in the United States.

The Company has not authorised any offer to the public of securities in any member state of the European Economic Area other than Finland. With respect to each member state of the European Economic Area other than Finland which has implemented the Prospectus Directive (each, a “Relevant Member State”), no action has been undertaken or will be undertaken to make an offer to the public of securities requiring publication of a prospectus in any Relevant Member State. As a result, the securities may only be offered in Relevant Member States (a) to any legal entity which is a qualified investor as defined in the Prospectus Directive; or (b) in any other circumstances falling within Article 3(2) of the Prospectus Directive. For the purposes of this paragraph, the expression “an offer of securities to the public” means the communication in any form and by any means of sufficient information on the terms of the offer and the securities to be offered so as to enable an investor to decide to exercise, purchase or subscribe the securities, as the same may be varied by any measure implementing the Prospectus Directive in that Relevant Member State, and the expression “Prospectus Directive” means Directive 2003/71/EC (and amendments thereto, including the 2010 PD Amending Directive, to the extent implemented in the Relevant Member State), and includes any relevant implementing measure in the Relevant Member State and the expression “2010 PD Amending Directive” means Directive 2010/73/EU.

The information contained herein shall not constitute a public offering of shares in the United Kingdom. This document is only being distributed to and is only directed at (i) persons who are outside the United Kingdom or (ii) to investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (iii) high net worth companies, and other persons to whom it may lawfully be communicated, falling within Article 49(2) of the Order (all such persons together being referred to as “relevant persons”). Any investment activity to which this document relates will be only available to, and will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this announcement or any of its contents.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 2

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 4

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 7

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 2

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading

Top 5 Most Recently Viewed Articles

SKK Holdings Limited Announces Pricing for Share IPO Offering

Updated Category News Views 65

SKK Holdings Limited Announces Share Pricing for IPO SKK Holdings Limited (“SKK” or the “Company”) (Nasdaq: SKK), a specialized civil engineering service provider in subsurface utility works, has proudly announced the pricing of its initial public offering. The Company will offer 2,500,000 ordinary shares at a public offering price of $4.00 per share, yielding...

Continue Reading
Antelope Enterprise: Financial Performance Insights for 2024

Updated Category News Views 149

Antelope Enterprise Holdings Limited (NASDAQ: AEHL) hit the financial report stage hard back in mid-2024, flaunting numbers that tell quite the tale of both triumphs and tribulations. This company was hustling across two growing fronts: the fast-paced world of livestreaming ecommerce and the burgeoning energy sector down in Texas. Their half-year performance review...

Continue Reading
Olivier Falut Steps Into CFO Role at EUROAPI to Drive Growth

Updated Category News Views 344

Olivier Falut Joins EUROAPI as the New Chief Financial Officer EUROAPI is excited to announce the appointment of Olivier Falut as its new Chief Financial Officer, effective immediately. Olivier will be an integral member of the Executive Committee, succeeding Evelyne Nguyen. Evelyne will ensure continuity and a smooth transition within the company through her support...

Continue Reading
OPEXUS and Casepoint Join Forces for Growth and Innovation

Updated Category News Views 261

OPEXUS and Casepoint Unite for Strategic Growth In a significant development in the technology sector, OPEXUS, a frontrunner in government process management software, and Casepoint, an innovator in data discovery technology, have announced their merger. This significant move comes along with a majority investment from Thoma Bravo, a renowned software investment firm...

Continue Reading
MeiraGTx Holdings: An In-Depth Look at Future Potential

Updated Category News Views 69

MeiraGTx Holdings plc (NASDAQ:MGTX) was a clinical-stage gene therapy firm making waves back in 2024. The company announced a pivotal financial move, securing $50 million through equity financing at $4 per share, largely thanks to a $30 million investment from Sanofi (NYSE:SNY). While this funding boosted MGTX’s war chest, traders were already whispering about the heavy...

Continue Reading